Q3 2025 Cytokinetics Inc Earnings Call Transcript

Nov 5, 2025 / 09:30 PM GMT

Release Date Price: $59.19 (-0.72%)

Transcript 10-Q8-K

Key Points

Positve

Cytokinetics Inc (CYTK) made significant progress towards the potential FDA approval of Aficamptin for patients with obstructive hypertrophic cardiomyopathy (OHCM).
The company completed all Good Clinical Practice (GCP) inspections by the FDA with no observations noted, indicating strong compliance.
Cytokinetics Inc (CYTK) presented positive primary results from the Maple HCM trial, demonstrating the superiority of Aficamptin over metoprolol in patients with OHCM.
The company has a strong balance sheet, bolstered by a convertible note offering, providing financial flexibility ahead of the potential launch of Aficamptin.
Cytokinetics Inc (CYTK) is well-prepared for the commercial launch of Aficamptin, with a seasoned cardiovascular sales team and comprehensive patient support programs in place.

Negative

Cytokinetics Inc (CYTK) reported a net loss of $306.2 million for the third quarter of 2025, a significant increase from the previous year's loss.
The company's R&D and G&A expenses increased compared to the same period in 2024, primarily due to advancing clinical trials and commercial readiness investments.
The approval and launch of Aficamptin in the EU and China are still pending, with regulatory processes ongoing.
There is uncertainty regarding the finalization of the REMS program with the FDA, which is crucial for the approval of Aficamptin.
The company faces challenges in expanding the market penetration of cardiac myosin inhibitors (CMIs), with current penetration estimated at only 15-20% of the eligible OHCM market.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CYTK.OQ - Cytokinetics Inc
Q3 2025 Cytokinetics Inc Earnings Call
Nov 05, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by and welcome to the Cytokinetics Q3 2025 earnings conference call.

This call is being recorded and all participants are in a listen-only mode. After the speaker's remarks, we will open the call to questions. We will allow for one question per part participant.

If you would like to ask a question during that time, simply press the star followed by the number one on your telephone keypad. If you would like to withdraw your question, press 1 again once more.

I would now like to turn the call over to Diane Weiser, cytokinetic's senior Vice President of corporate affairs. Please go ahead.

--------------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.